Nektar Therapeutics
http://www.nektar.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nektar Therapeutics
Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
Abbott, BD, Quidel OTC COVID-19 Tests Granted Emergency Use Authorization In US
FDA grants emergency use authorization to OTC COVID-19 testing products as it targets allowing workplaces, schools and communities to access tools needed to screen for the virus rapidly and accurately.
FDA Grants Emergency Use Authorization To Variety Of OTC COVID-19 Tests
The US agency has granted emergency use authorization to consumer COVID-19 testing products from Quidel, Abbott and BD.
Alkermes Cites IL-2 Differentiation As It Moves To Phase III, And Seeks A Partner
Executives pointed to the IL-2 variant drug’s potential for subcutaneous administration as a key differentiator from other IL-2 variant programs.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Aerogen, Inc.
- Inhale Therapeutic Systems, Inc.
- Inheris Biopharma, Inc.
- Nektar Therapeutics (India) Private Limited